Abstract
Background
Esophagectomy following neoadjuvant chemotherapy (NAC) is a standard treatment for resectable advanced esophageal cancer in Japan. However, approximately 10 % of patients with resectable advanced esophageal cancer experience recurrence within 6 months.
Methods
One hundred twenty-eight patients with resectable advanced esophageal cancer underwent NAC between October 2008 and July 2015 in Kumamoto University Hospital. Among them, 82 patients with esophageal squamous cell carcinoma (SCC), who underwent curative esophagectomy without adjuvant treatment, were eligible. Clinicopathological factors correlated with early recurrence were retrospectively analyzed.
Results
Of 82 patients, 14 (17 %) recurred within 6 months after surgery. The logistic regression analysis suggested that CRP before NAC ≥ 0.5 mg/dl [hazard ratio (HR) 33.8, 95 % confidence interval (CI) 2.767–413.9; p = 0.006), presence of poorly differentiated SCC component (HR 138, 95 % CI 5.339–3576; p = 0.003), and pathological vessel invasion (HR 16.3, 95 % CI 1.960–136.1; p = 0.010) were candidates for independent risk factors of early recurrence. Patients with at least two factors frequently recurred (82 %). Of 14 patients with early recurrence, 13 (93 %) had a distant metastasis.
Conclusions
Patients with resectable advanced esophageal cancer with at least two factors of CRP before NAC ≥ 0.5 mg/dl, presence of poorly differentiated SCC component, and pathological vessel invasion might be at high risk for early recurrence after esophagectomy following NAC. These patients might be considered for additional treatment and should be meticulously followed up after treatment.
Similar content being viewed by others
References
Zacherl J (2014) The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer. Dig Dis 32:171–175
van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
Allum WH, Stenning SP, Bancewicz J et al (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27:5062–5067
Ando N, Iizuka T, Ide H et al (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol 21:4592–4596
Boonstra JJ, Kok TC, Wijnhoven BP et al (2011) Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 19(11):181
Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74
Kelsen DP, Winter KA, Gunderson LL et al (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25:3719–3725
Allum WH, Stenning SP, Bancewicz J et al (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27:5062–5067
Nomura M, Oze I, Abe T et al (2015) Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemother Pharmacol 76:357–363
Stiles BM, Salzler GG, Nasar A et al (2015) Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomy. Eur J Cardiothorac Surg 48:455–460
Kosugi S, Kanda T, Yajima K et al (2011) Risk factors that influence early death due to cancer recurrence after extended radical esophagectomy with three-field lymph node dissection. Ann Surg Oncol 18:2961–2967
Zhu ZJ, Hu Y, Zhao YF et al (2011) Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg 91:1502–1508
Davies AR, Pillai A, Sinha P et al (2014) Factors associated with early recurrence and death after esophagectomy for cancer. J Surg Oncol 109:459–464
Edge SB, Byrd DR, Compton CC et al (2009) AJCC Cancer Staging Manual, 7th edn. Springer, New York
Watanabe M, Nagai Y, Kinoshita K et al (2011) Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion 83:146–152
Society of Thoracic Surgeons (2013) Risk-Adjusted Morbidity and Mortality for Esophagectomy for Cancer. Available: http://www.sts.org/quality-research-patient-safety/quality/quality-performance-measures [accessed Feb 28, 2016]
National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE). United States Department of Health and Human Services. Available: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf#search=‘http%3A%2F%2Fevs.nci.nih.gov%2Fftp1%2FCTCAE%2F+CTCAE_4.03_20100614_QuickReference_57.pdf [accessed Feb. 28, 2016]
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
Murata N, Soga Y, Iida O et al (2015) Complex relationship of body mass index with mortality in patients with critical limb ischemia undergoing endovascular treatment. Eur J Vasc Endovasc Surg 49:297–305
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Watanabe M, Baba Y, Yoshida N et al (2014) Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol 21:2838–2844
Wu D, Xu J, Yu G et al (2013) Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. Hepatogastroenterology 60:99–106
Zhan C, Shi Y, Lu C, Wang Q (2013) Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer. Dis Esophagus 26:746–753
Imamura Y, Watanabe M, Nagai Y et al (2012) Lymphatic vessel invasion detected by the D2-40 monoclonal antibody is an independent prognostic factor in node-negative esophageal squamous cell carcinoma. J Surg Oncol 105:277–283
Bai B, Ma W, Wang K et al (2013) Detection of D2-40 monoclonal antibody-labeled lymphatic vessel invasion in esophageal squamous cell carcinoma and its clinicopathologic significance. Cancer Biol Med 10:81–85
Fujiwara H, Suchi K, Okamura S et al (2011) Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 103:62–68
Lindenmann J, Fink-Neuboeck N, Koesslbacher M et al (2014) The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment. J Surg Oncol 110:645–650
Wang CY, Hsieh MJ, Chiu YC et al (2009) Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92:270–275
Ohira M, Kubo N, Masuda G et al (2015) Glasgow Prognostic Score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res 35:4897–4901
Xu XL, Yu HQ, Hu W et al (2015) A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One 10:e0138657
Hirahara N, Matsubara T, Hayashi H et al (2015) Impact of inflammation-based prognostic score on survival after curative thoracoscopic esophagectomy for esophageal cancer. Eur J Surg Oncol 41:1308–1315
Groblewska M, Mroczko B, Sosnowska D et al (2012) Interleukin 6 and C-reactive protein in esophageal cancer. Clin Chim Acta 413:1583–1590
Chen MF, Kuan FC, Yen TC et al (2014) IL-6-stimulated CD11b + CD14 + HLA-DR-myeloid-derived suppressor cells are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget 5:8716–8728
Le Bras GF, Taylor C, Koumangoye RB et al (2015) TGFβ loss activates ADAMTS-1-mediated EGF-dependent invasion in a model of esophageal cell invasion. Exp Cell Res 330:29–42
Chen MF, Lu MS, Chen PT et al (2012) Role of interleukin 1 beta in esophageal squamous cell carcinoma. J Mol Med 90:89–100
Szlosarek P, Charles KA, Balkwill FR (2006) Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42:745–750
Nakatsu T, Motoyama S, Maruyama K et al (2012) Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today 42:652–658
Sudarshan M, Alcindor T, Ades S et al (2015) Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Ann Surg Oncol 22:324–330
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Naoya Yoshida and coauthors have no conflict of interest in relation to this article.
About this article
Cite this article
Yoshida, N., Baba, Y., Shigaki, H. et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. Int J Clin Oncol 21, 1071–1078 (2016). https://doi.org/10.1007/s10147-016-0994-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-016-0994-9